ASA Makes Recommendations to FDA for Opioid Conversion Labeling
In a letter to the FDA, the American Society of Anesthesiologists has addressed public health concerns associated with the use of equianalgesic opioid conversion tables and has recommended a staged approach for opioid conversion labeling.
According to ASA, "opioid conversion must emphasize the goal of safety by specifying the potential for dose adjustments after calculation of the equianalgesic dose."
Download the full letter on the ASA website.
More Articles on Anesthesia:
Study: Prescription Painkiller Overdose Deaths in Women Spike 400% in 10 Years
Dr. Walter Schuyler Joins Pain Specialists of Charleston
Sibley Medical Center to Open Pain Management Clinic, Adds Dr. J. Richard Waggoner
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- How Physician Thinking Changes After Working in ACOs
- 2014 Financial Impact Analysis Doesn't Stop With CMS' Final Rule: Don't Neglect CMS NCCI Edits
- 4 Drivers of Recent M&A Activity in Healthcare
- 8 Reasons to Outsource Medical Billing Services
- 5 ICD-10 Transition Considerations Medical Practices Have Likely Not Thought About